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Abstract: Background: Vitiligo is characterized by a lack of pigmentation in the skin. To date, there are no studies that analyze 
the changes in gene expression in the skin of vitiligo patients in response to narrow-band ultraviolet B (nb-UVB) phototherapy 
treatment. 
oBjective: Explore the usefulness of new generation RNA sequencing in the identification of gene expression changes in the 
skin of vitiligo patients treated with nb-UVB phototherapy. 
Methods: Four skin biopsies (4mm in diameter) were collected from 45 Mexican vitiligo vulgaris patients, 2 specimens before 
and 2 after treatment with nb-UVB phototherapy, obtained from pigmented and non-pigmented tissue. RNA extracted from 
the biopsies was analyzed using the Illumina TruSeq Targeted RNA Expression protocol to study the expression of genes 
that participate in pathways of skin homeostasis. The 2 groups were compared using Student’s t-test and the Mann-Whitney 
U-test. 
results: The expression analysis identified differences in 12 genes included in this study after comparing the samples obtained 
before and after treatment: 5 genes involved in skin pigmentation, 2 genes involved in apoptosis, 2 genes involved in cell sur-
vival, 2 genes involved in oxidative stress responses and 1 gene involved in signal transduction mechanisms (p<0.05). 
study liMitations: The small size of skin biopsies limits the amount of RNA obtained, the number of genes to be analyzed and 
the use of conventional techniques such as RT-qPCR. 
conclusion: We demonstrated usefulness of new generation RNA sequencing in the identification of gene expression changes, 
in addition to identifying new targets in the study of vitiligo.
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INTRODUCTION
Vitiligo belongs to a family of cutaneous diseases, charac-
terized by a lack of pigmentation in the skin.1 This disease affects 
between 0.1% and 2% of the world’s population; however, its inci-
dence varies considerably among the populations or ethnic groups 
analyzed and is estimated to be 0.14% in Russia, between 1% and 
2.5% in the United States and Japan,² and high in Mexico (4%) and 
India (8.8%).¹,³
The causes of vitiligo are complex and not yet fully under-
stood. Several hypotheses and theories have been developed to ex-
plain the depigmentation and melanocyte destruction observed in 
this condition; however, these theories do not explain the full spec-
trum of this disease.4 Thus, the clinical data, embryonic origin of the 
melanocytes, association with autoimmune disorders, and presence 
of relatives affected with this disease, among other factors, should 
nv stigAtion
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be considered, suggesting that vitiligo results from a combination of 
environmental, autoimmune and genetic factors, and several theo-
ries have been proposed.5,6
Studies worldwide have explored genes that are potential-
ly involved in the development of vitiligo and other autoimmune 
diseases using gene expression analysis studies, candidate gene as-
sociation studies, genetic linkage studies, and genomic association 
studies (GWAS).7Gene expression studies performed on skin biop-
sies obtained from patients with vitiligo have enabled the analyses 
of changes in the expression patterns of several genes associated 
with immunomodulation,7 melanogenesis, and regulation of the de-
velopment and survival of melanocytes.8-11
To date, no fully effective treatment for vitiligo has been 
identified. Techniques promoting repigmentation have been used, 
such as narrow-band ultraviolet B light (nb-UVB), which is current-
ly considered the treatment of choice for vitiligo.12 This therapy uses 
a light spectrum of 311nm, presenting a penetrance to the basal lay-
er of the epidermis, which induces local immunosuppression and 
stimulates the proliferation of melanocytes in the skin and in the 
external epithelial root sheath of the hair follicle, thereby stimulat-
ing melanogenesis and the production of melanocyte-stimulating 
hormone (MSH).12-14
Currently, there are no studies analyzing the changes in 
gene expression in the skin of subjects in response to the treatment 
of vitiligo, particularly the application of nb-UVB treatment. Using 
the currently available molecular tools, including reverse transcrip-
tion polymerase chain reaction (RT-PCR) as well as transcript iden-
tification and gene expression quantification through RNA sequenc-
ing (RNA-seq) analysis, we can efficiently analyze the expression 
profiles of multiple genes present in cells and tissues under patho-
logical and non-pathological human conditions, among other con-
ditions.15-18 In particular, RNA-seq using next-generation sequencing 
(NGS) also facilitates a more accurate measurement of the levels of 
transcript expression, even the presence of isoforms in the analyzed 
samples.19 TruSeq RNA Targeted sequencing can effectively detect 
changes in patterns of gene expression by simultaneously analyz-
ing a large variety of selected targets with custom designs, using 
smaller sample amounts, shorter processing times and lower costs 
than other technologies (qPCR and Microarray).20,21 This technology 
has previously been applied in the identification of expression pro-
files in other dermatological diseases, such as psoriasis and lupus 
erythematosus, suggesting that TruSeq RNA Targeted sequencing 
could be a useful tool for vitiligo.22-24 However, the discrimination 
power of this method has not been explored in vitiligo.
In a previous study conducted by our research group on 
skin biopsies obtained from a smaller number of untreated vitiligo 
patients and healthy controls, we detected changes in the expres-
sion of the genes involved in a wide variety of biological processes, 
including signaling, apoptosis, oxidative stress control, cell survival 
and pigmentation (unpublished data). Using the information from 
the gene expression profiles and the addition of other genetic targets 
identified by the previously mentioned methods, valuable informa-
tion concerning gene expression patterns, clinical classification, and 
the effectiveness of the treatment could be obtained using RNA-seq.
Thus, the objective of the present study was to explore the 
use of RNA-seq technology for the identification of changes in the 
expression profiles of selected genes in skin biopsies obtained from 
vitiligo patients before and after treatment with nb-UVB; the present 
study used NGS TruSeq Targeted RNA Expression from Illumina.
METHODS
 Patient Selection, interview and Informed Consent (CI) 
signature
This study included a total of 45 adult patients of both sexes, 
who were diagnosed with vitiligo vulgaris, defined as a condition 
with depigmentation between 10% and 80% of the body surface, 
and who were candidates for treatment with nb-UVB phototherapy, 
without having received treatments in the last 6 months. Patients 
who did not meet these selection criteria, with severe or poorly 
controlled systemic diseases, cancer, photosensitivity, infection or 
injury in the treated area were excluded. For female subjects, preg-
nant women were excluded. These patients were evaluated in two 
groups: 23 patients with active vitiligo vulgaris (AVV, in which the 
lesions grew or new lesions appeared in a period of 6 months) and 
22 patients with stable vitiligo vulgaris (SVV, in which there was no 
growth or the appearance of new lesions in a period of 6 months).
Each subject participating in this study was asked to pro-
vide informed consent, after having the scope of the research pro-
tocol and the benefits and risks explained. The participants were in-
terviewed and clinically evaluated by dermatologists to confirm the 
diagnosis of vitiligo. In addition, demographic information, personal 
data, and personal history of the disease (e.g., age of appearance of 
the first macula, number and distribution of lesions, and attributable 
causes) were obtained through a survey, and whether the patient re-
ceived any previous treatment, the type of response observed, family 
history of vitiligo, association with other autoimmune diseases, po-
tential exposure to stressful situations or psychological disorders, and 
measures of height and weight were also determined.
This protocol and the informed consent forms were ap-
proved by the Institutional Review Board and registered under the 
code DE13-001.
nb-UVB phototherapy treatment
Each patient was treated with nb-UVB phototherapy per-
formed 2 times a week for a period of 6 months (for a total of 48 
sessions) using a DAAVLIN Phototherapy Unit Model Spectra 
311/350nm (Bryan, Ohio, USA) with a starting dose of 150mJ/cm2, 
with increments of 50mJ/cm2 every third session depending on the 
phototype of the patient, until the minimum erythema dose was 
reached. This dose was maintained once the response was obtained. 
If the patient presented any reaction, then this dose was decreased 
to the previous tolerated dose.
Treatment follow-up was documented through baseline ico-
nography and at 1, 3 and 6 months after initiation of treatment. The 
clinical results (i.e., changes of repigmentation experienced by the 
patient after 6 months of treatment) were evaluated by 2 indepen-
dent and double-blind investigators.
The iconography was obtained using a Sony Exmor DSC-
HX1 9.1 megapixel camera (Shinagawa-ku, Tokyo, Japan).
Biological samples
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Blood sample
Analyses to assess hematological biometry (BH), blood 
chemistry tests, antinuclear antibodies and thyroid profile were per-
formed to rule out the presence of concomitant autoimmune diseas-
es in the participants.
Skin biopsies
Skin biopsies, obtained by skin punch (4 mm diameter) of the 
pigmented areas and from lesions before and after treatment, were 
used for the mRNA extraction and subsequent gene expression analy-
sis. In total, 4 biopsies were collected from each patient: 2 samples were 
collected during the protocol (one of non-affected skin and one of the 
vitiligo lesions) and 2 samples were collected at the end of photothera-
py treatment (one of skin that repigmented after treatment and another 
of a vitiligo lesion that did not repigment at the end of treatment).
The biopsies were stabilized in RNAlater® (Thermo Fisher 
Scientific, Inc. Waltham, MA, USA) according to the manufacturer’s 
instructions and stored at -80°C until the time of processing.
RNA extraction
RNA was extracted from the skin biopsies stored in RNAlat-
er® using the RNeasy Fibrous Tissue Mini Kit (Qiagen Inc. Valencia, 
CA, USA) according to the manufacturer’s instructions.
Verification	of	RNA	quantity	and	quality
The amount of total RNA was determined using spectro-
photometric microvolume quantification using a NanoDrop 8000 
(Thermo Fisher Scientific, Inc. Waltham, MA, USA) and confirmed 
using quantification according to the fluorometric method using the 
Qubit® RNA-BR assays Kit for Qubit 2.0 (Thermo Fisher Scientific, 
Inc. Waltham, MA, USA). The quality of the RNA was determined 
through capillary electrophoresis using the Experion Automated 
Electrophoresis System (Bio-Rad, Hercules, CA, USA) through the 
determination of the ratio of 18S to 28S ribosomal subunits.
cDNA synthesis for sequencing
To perform this assay, reverse transcription was performed 
using 100 μg of total DNase-treated RNA extracted from patient 
biopsies, ProtoScript® reverse transcriptase (New England Biolabs, 
Ipswich, MA, USA), and the TruSeq Targeted RNA Expression pro-
tocol from Illumina for NGS.
Analysis of gene expression
The cDNAs generated from the skin biopsies of patients be-
fore and after treatment were used to perform the expression anal-
ysis of a group of 29 genes involved in key pathways implicated in 
the pigmentation and homeostasis of the skin cells8-10,25-42 using the 
Illumina MiSeq® Reagent Kit v3 (150 cycle) and the TruSeq Targeted 
RNA Custom Panel Kit (Chart 1).
Data obtained from RNA-seq were analyzed using the 
available TruSeq Targeted RNA tool BaseSpace (https://basespace.
illumina.com). The results were exported and normalized to the to-
tal number of counts. The figures were generated using R statistical 
language (https://cran.r-project.org/).
Statistical analysis
The collected data were analyzed using SPSS software ver-
sion 17.0 (SPSS, Inc. Chicago, IL, USA). For the demographic data 
and to define the variables, descriptive statistics were used for 
both the vitiligo injury group and the normal skin group. To exam-
ine normality, Kolmogorov-Smirnov and Shapiro-Wilk tests were 
performed. According to the type of distribution presented by the 
groups (normal or non-normal), the 2 groups were compared using 
Student’s t-test and the Mann-Whitney U-test. A value of P ≤ 0.05 
was considered significant.
RESULTS
Demographic analysis
We included 45 patients diagnosed with vitiligo from the 
State of Nuevo León, Mexico; the patients consulted the Derma-
tology department of the University Hospital Dr. José Eleuterio 
González. The samples were categorized according to the vitiligo 
activity in: 22 patients as stable type disease (14 males and 8 females) 
and in 23 patients as active type disease (10 male and 13 female). 
The mean age of the patients was 41.58 ± 14.36 years (minimum 19 
years, maximum 73 years, 39.79 ± 12.18 years for male subjects and 
40.00 ± 16.43 years for female subjects).
Response to treatment
After independent assessments by 2 dermatologists, 42 of 
the 45 subjects included in the expression analysis showed respons-
es to treatment (93.33%, 20 Active [44.44%], 22 Stable [48.89%]). The 
three subjects who did not present repigmentation after treatment 
had active vitiligo (6.67%).
Expression analysis
The heat maps generated after comparing the expression pat-
terns from the samples obtained before and after treatment (Figure 
1) enabled the identification of differences between the expression 
patterns of pigmented skin (not affected, and repigmented after treat-
ment) and non-pigmented skin (vitiligo and tissue sample that did 
not repigment), organized into 2 main clades in the heat map.
In addition, significant expression patterns were found 
in three pigment-related genes: DopachromeTautomerase (DCT), 
Melan-A (MLANA) and Tyrosinase-Related Protein (TYRP1) gene, 
which are over expressed in pigmented skin (p<0.05).
When grouping the samples according to the type and sub-
type of pigmentation (with pigment and without pigment), gender 
(female or male), age, type of vitiligo (active or stable), and degree 
of response to treatment (less than 10% improvement, 10%-30% 
improvement and more than 30% improvement), we observed 
the same patterns of over expression in DCT, MLANA and TYRP1 
genes (related to skin pigmentation) (Figure 2).
No differences in the type of vitiligo were observed among 
skin samples from subjects with active or stable vitiligo.
 Comparison of the skin expression patterns before and 
after treatment
Using Student’s t-test, we compared the mean values for 
the expression patterns of the analyzed genes in pigmented and 
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chart 1: Genes included in TruSeq Targeted RNA Custom Panel Kit and the functions and routes involved in the development of vitiligo
Pathway Gene Function
Pigmentation DCT8,30 Involved in regulating eumelanin and pheomelanin levels
MC1R8 Encodes the receptor protein for melanocyte-stimulating hormone (MSH); controls melanogenesis
MC4R8 Encoded a protein that interacts with adrenocorticotropic and MSH hormones and is mediated by 
G proteins
POMC8 Encodes a preproprotein that undergoes extensive, tissue-specific, post-translational processing via 
cleavage. One peptide produced from the POMC protein is α-MSH involved in regulating the pig-
ment-producing cells of the skin and hair (melanocytes), where it binds to melanocortin 1 receptor 
(MC1R)
TYRP18,30 Encodes a melanosomal enzyme that belongs to the tyrosinase family and plays an important role 
in the melanin biosynthetic pathway
MLANA30 Involved in melanosome biogenesis
PHACTR227 Phosphatase and actin regulator 2
Apoptosis BAX25 BCL2-associated X protein that acts as an anti- or pro-apoptotic regulator that is involved in a wide 
variety of cellular activities
BCL29,25 Encodes an integral outer mitochondrial membrane protein that blocks apoptotic death
BCL326 Involved in the regulation of cell proliferation and contributes to transcriptional regulation of NFKB
CASP325,29 Is a member of the cysteine-aspartic acid protease (caspase) family; plays a central role in the execu-
tion-phase of cell apoptosis
CASP731 Is a member of the cysteine-aspartic acid protease (caspase) family; plays a central role in the execu-
tion-phase of cell apoptosis
CASP829 Is a member of the cysteine-aspartic acid protease (caspase) family; plays a central role in the execu-
tion-phase of cell apoptosis.
CASP1032 Is a member of the cysteine-aspartic acid protease (caspase) family; plays a central role in the execu-
tion-phase of cell apoptosis
CFLAR28 CASP8 and FADD-like apoptosis regulator, is a regulator of apoptosis and is structurally similar to 
caspase-8 
FASLG35 Fas ligand (TNF superfamily, member 6); induction of apoptosis triggered by binding to FAS
TNF37 Tumor necrosis factor, involved in the regulation of a wide spectra of biological processes, including 
cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation
TNFRSF1A33 One of the major receptors for the tumor necrosis factor-alpha; activates NF-kappa B, mediates 
apoptosis, and functions as a regulator of inflammation
Oxidative stress GGT134 Involved in the maintenance of intracellular GSH levels. It is part of the cellular antioxidant defense 
mechanism
CCBL242 Cysteine conjugate-beta lyase 2, involved in the regulation of oxidative stress
GPD138 Glycerol-3-phosphate dehydrogenase 1, involved in the redox metabolism
TXN39 Thioredoxin, inhibits oxidative stress and caspase 3 activity
Cell survival CAPN310 A major intracellular protease involved in melanocyte survival
MITF9,30 Involved in melanocyte survival, controls the expression of genes that relate melanin synthesis
CDC5L36 Involved in cell cycle control
MAPK140 Mitogen-activated protein kinase 1, involved in cell proliferation and differentiation
Signal 
transduction
CSNK1G340 Participates in the Wnt signaling pathway
NFKB126 Nuclear Factor Kappa B Subunit 1, is a transcription regulator that stimulates the expression of 
genes involved in a wide variety of biological functions
WNT7A41 Wnt Family Member 7A, implicated in oncogenesis and several developmental processes
Endogenous 
control / 
constitutive 
expression
TPT1 Tumor protein, translationally controlled 1, involved in calcium binding and microtubule stabiliza-
tion. Endogenous control / constitutive expression
GAPDH Glyceraldehyde-3-phosphate dehydrogenase. Endogenous control / constitutive expression
non-pigmented skin before and after treatment, and significant dif-
ferences were observed in 12 genes related to the mechanisms of 
pigmentation, apoptosis, cell life, oxidative stress and cellular sig-
naling mechanisms (Table 1).
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Among these genes, we observed statistically significant 
differences in DCT (involved in the regulation of eumelanin and 
pheomelanin levels), TYRP1 (involved in melanin biosynthesis), 
MC1R (melanocortin receptor 1 involved in the control of melano-
genesis), and MLANA (involved in the biogenesis of melanosomes), 
particularly when comparing pigmented skin (not affected prior to 
treatment and repigmented skin) to skin that did not show pigment 
(vitiligo skin and skin that did not repigment after treatment), ac-
counting for the degree of pigment observed in the respective skin 
types (p <0.05). However, in the MC4R gene (melanocortin receptor 
4, which interacts with adrenocorticotropin and MSH in skin pig-
mentation), we only observed a statistically significant difference in 
the degree of expression in the vitiligo skin before treatment and 
not repigmented after treatment (p = 0.05), where vitiligo skin dis-
played reduced expression.
For genes involved in apoptosis mechanisms, we observed 
differences in two of the genes selected for this study (p <0.05), CASP3 
(cysteine protease 3, processed by caspases 8, 9 and 10 and participat-
FIgure 1: Heat map of expression 
patterns from biopsies obtained be-
fore and after treatment. In the figure, 
the vertical axis represents the gene 
expression patterns of the samples 
obtained for each gene (horizontal). 
Sample color codes indicate tissue 
with vitiligo (blue), unaffected skin 
(black) before treatment, repigmen-
ted skin (green) and vitiligo that did 
not repigment (red) after nb-UVB 
treatment. The red coloration within 
the heat map corresponds to over ex-
pression, while white corresponds to 
intermediate expression, and blue cor-
responds to sub expression
FIgure 2: Heat map of expression pat-
terns grouped according to vitiligo 
type and disease improvement. At 
the top of the heat map, the following 
study groups are represented: type 
and subtype of sample according to 
pigmentation (black and red), and 
improvement (black corresponding to 
less than 10% improvement, red cor-
responding to 10%-30% improvement 
and green corresponding to more than 
30% improvement). The vertical axis 
represents the expression patterns of 
the samples obtained for each of the 
genes (horizontal). The red color wi-
thin the heatmap corresponds to over 
expression, while white corresponds 
to intermediate expression, and blue 
corresponds to sub expression
The data are shown as the means ± standard deviation. (A) Unaffected vs Vitiligo skin; (B) Unaffected vs Regimented; (C) Unaffected vs Not repigmented; (D)Vitiligo vs Repigmented; (E) 
Vitiligo vs Not repigmented; (F) Repigmented vs Not repigmented. (*) Denotes p<0.05, and (**) denotes p<0.01.
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table 1: Comparison of gene expression patterns in the skin biopsy of vitiligo patients before and after treatment
Skin biopsy expression
Pathway GENE Unaffected skin 
(Means ± SD)
Vitiligo skin 
(affected) 
(Means ± SD)
Repigmented after treat-
ment (Means ± SD)
Not Repigmented after 
treatment (Means ± SD)
P-value
Pigmentation DCT 2.965 ± 0.554 0.714 ± 0.947 2.729 ± 0.804 0.590 ± 0.897 A**; C**; 
D**;F**
MC1R 1.148 ± 0.822 0.602 ± 0742 1.013 ± 0.788 0.529 ± 0.621 A**; C**; 
D**; F**
MC4R 0.113 ± 0.387 0.000 ± 0.000 0.083 ± 0.316 0.076 ± 0.252 E*
MLANA 2.793 ± 0.505 0.476 ± 0.745 2.488 ± 0.653 0.454 ± 0.699 A**; B*; 
C**;D**; F**
TYRP1 3.544 ± 0.343 1.214 ± 0.920 3.451 ± 0.463 1.230 ± 0.983 A**; C**; 
D**; F**
Apoptosis CASP3 2.361 ± 0.692 2.521 ± 0.302 2.335 ± 0.545 2.268 ± 0.703 D*; E*
TNFRSF1A 3.158 ± 0.310 3.179 ± 0.246 3.054 ± 0.303 3.136 ± 0.230 D**
Cell survival CDC5L 3.377 ± 0.199 3.373 ± 0.174 3.291 ± 0.190 3.359 ± 0.250 B*; D*
MITF 3.014 ± 0.522 2.862 ± 0.248 2.980 ± 0.238 2.643 ± 0.605 C**; D*; E*; 
F**
Cellular 
Oxidative 
Stress 
Response 
GPD1 2.624 ± 0.779 2.668 ± 0.753 2.805 ± 0.552 2.336 ± 0.907 E*; F**
TXN 4.203 ± 0.238 4.310 ± 0.128 4.289 ± 0.136 4.315 ± 0.132 A**; B*;C**
Signal 
transduction
CSNK1G3 2.252 ± 0.662 2.408 ± 0.365 2.238 ± 0.703 1.981 ± 0.944 E**
ing in the execution of the cell apoptosis signaling cascade, activating 
caspases 6, 7 and 9) and TNFRS1A (tumor necrosis factor receptor su-
per family member 1A), which induces cell death signaling through 
caspase 8 (Table 1). Both genes were over expressed in the skin of pa-
tients with vitiligo, suggesting that the induction of an extrinsic mecha-
nism of apoptosis is involved in the pathogenic mechanism of vitiligo.
However, the analysis of the expression patterns of the genes 
involved in melanocyte mechanisms (Table 1) indicates that two of 
the selected genes showed differential expression patterns between 
the skin types (p <0.05). The differential expression patterns of the 
CDC5L gene (involved in the control of the cell cycle) in unaffected 
and vitiligo versus repigmented skin after treatment were reduced in 
the repigmented skin. The expression of the MITF gene (that controls 
the expression of genes related to melanin synthesis and melanocyte 
survival) was higher for pigmented tissues (non-affected and repig-
mented after treatment) compared to vitiligo skin before treatment 
and in affected skin that did not repigment after treatment (Table 1).
When analyzing the genes involved in responses to oxida-
tive stress (Table 1), the GPD1 gene (involved in the Redox metab-
olism of the cell) was over expressed in tissue that did not repig-
ment after treatment. The TXN gene (involved in the inhibition of 
oxidative stress and activation of caspase 3) was over expressed in 
vitiligo skin and affected skin that did not repigment, accounting for 
the activation of mechanisms in response to apoptosis and oxidative 
stress generated by this cell death mechanism.
Finally, gene-related signaling pathways and signal transla-
tion mechanisms showed statistically significant differences when 
comparing the mean expression patterns observed for the CSNK1G3 
gene when analyzing vitiligo and affected skin that did not repig-
ment after treatment, which was reduced in the latter case (Table 
1). The product of the CSNK1G3 gene is a serine/threonine kinase 
that phosphorylates several proteins involved in the Wnt pathway, 
participating in cellular processes such as DNA repair, cell division, 
nuclear localization and membrane transport: all active processes in 
the cells of the skin and potentially involved in the synthesis, trans-
port and storage of the pigment.
DISCUSSION
In this research, a group of genes involved in skin pigmen-
tation, apoptosis and cell survival, oxidative stress and signal trans-
duction were selected to identify changes in the expression patterns 
of these genes in the skin of vitiligo patients undergoing treatment 
with nb-UVB phototherapy. Until recently, the relationship between 
the skin expression patterns of a group of genetic markers partici-
pating in the main routes involved in vitiligo, patients affected by 
this condition and responses to experienced standard treatments 
had not been documented.
For this purpose, nb-UVB phototherapy was applied for 6 
months, which is considered the standard treatment for vitiligo vul-
garis because of its effectiveness and safety.12
Evaluation by 2 dermatologists revealed that, consistent 
with patients undergoing treatment, 42 of the 45 subjects included 
in the expression analysis showed some degree of response to treat-
ment. The three subjects who did not present repigmentation after 
An Bras Dermatol. 2018;93(6):843-51.
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treatment presented active vitiligo (6.67%). Kumar et al. (2009) and 
Chen et al. (2005)43,44 reported similar results, showing a high per-
centage of responses to this type of treatment. However, the latter 
study did not describe the type of vitiligo or disease activity pre-
sented by patients who showed no response to treatment.
TruSeq RNA Targeted sequencing, unlike other methodol-
ogies for gene expression analysis, offers the following advantages: 
i) effective detection of changes in the “transcriptome” or patterns 
of gene expression through the simultaneous analysis of a variety 
of targets, ii) reduced processing and analysis times, iii) the use of 
small sample sizes to maximize analyses in subjects affected by this 
condition compared to the patterns present in the genes of healthy 
subjects, and iv) affordable costs.20,21 Due to the limited biological 
sample size, the numerous genetic targets to be analyzed and the 
need for economic resources for its development, this methodology 
is presented as the best option for analysis, even over RT-qCR. 
Using RNAseq technology for the analysis of gene expres-
sion, we observed differences in the expression patterns between 
the analyzed samples. The heat maps generated from the expres-
sion results obtained through the massive sequencing of Illumina 
TruSeq RNA (Figures 1 and 2) revealed similar expression patterns 
between the affected skin that repigmented after treatment and the 
unaffected skin of patients biopsied at the beginning of the study. 
Similar expression patterns were observed in the skin of vitiligo 
patients before treatment and affected skin that did not repigment 
after 6 months of phototherapy. Comparison of the different types 
of skin before and after treatment revealed the reduced expression 
of MLANA, DCT and TYRP1 genes, all of which are involved in 
skin pigmentation in non-pigmented skin compared to unaffected 
skin and repigmented skin after treatment. These results are con-
sistent with those described in the PhD thesis (2012) of Salinas45 and 
results published by Regazzetti et al. (2015), who validated a group 
of genes using real-time PCR, reporting low levels of MLANA, DCT 
and TYRP1 expression in affected skin (vitiligo lesions, compared to 
perilesional skin and non-affected – pigmented - patients).30
Statistical analysis of the expression patterns obtained from 
the skin samples before and after treatment revealed alterations in 
the expression of genes related to skin pigmentation, apoptosis, cell 
survival, oxidative stress and signal transduction mechanisms.
Reduced gene expression patterns in non-pigmented skin 
were observed in 5 of the 7 genes included in this study, correspond-
ing to MLANA, DCT and TYRP1, as previously mentioned, and 
MC1R and MC4R. These last two genes correspond to melanocortin 
receptors 1 and 4, which together with POMC form part of the hy-
pothalamic-hypophyseal-adrenal axis in the skin, which acts as a 
coordinator and enforcer of stress responses.8
Kingo et al. (2007) published the results of an expression 
analysis performed on genes participating in the melanocortin sys-
tem in skin biopsies obtained from non-pigmented lesions and pig-
mented (normal) skin from patients with vitiligo. These results were 
compared to the expression patterns of skin samples from healthy 
subjects, demonstrating that the expression of proopiomelanocortin 
and its receptors is reduced in the affected skin compared to the un-
affected skin of patients with vitiligo and controls. Recently, Nagui 
et al. (2015) reported the reduced expression of MC1R and POMC 
genes in affected skin obtained from a vitiligo lesion after analyzing 
only MC1R, MC4R and POMC.11
In contrast, Kingo et al.8,9 analyzed the expression profiles 
of the genes involved in pigmentation in biopsies of affected and 
unaffected skin of vitiligo patients, compared to the expression lev-
els observed in skin of normal control subjects, without immediate 
treatment, and our results correspond to the expression profile of a 
group of genes participating in 5 cell signaling pathways, including 
pigmentation, in biopsies from the affected and unaffected skin of 
patients obtained before and after nb-UVB treatment.
When analyzing the total RNA from each of the biopsies ob-
tained from the patients, changes in the expression profiles were ob-
served in most of the selected genes. In pigmentation, the genes that 
presented differential expression profiles before and after treatment 
were DCT, MC1R, MC4R, MLANA and TYRP1. Differences were de-
tected after comparing the expression profiles of skin biopsies with 
pigment (non-affected skin and affected skin that repigmented after 
treatment) vs. non-pigmented biopsies (biopsies of vitiligo skin and 
biopsies of affected skin that did not repigment after treatment). In 
addition, there were no statistically significant differences between 
the biopsies with pigment, obtained before and after phototherapy 
application. The same phenomenon was observed among biopsies 
without pigment, indicating that, once the treatment was applied, 
the expression profile of the skin underwent changes favoring the 
manifestation of the final pigmented phenotype. In skin that recov-
ered pigmentation, the expression patterns were similar or slightly 
higher in genes related to pigment.
The pigmentation gene expression results obtained in the pres-
ent study reaffirm those of Kingo et al. (2007, 2008) on biopsies before 
treatment8,9 and are consistent with those of Nagui et al. (2015) in the 
pigment routes.11However, we excluded the participation of POMC in 
this process because no statistically significant difference in the expres-
sion profile of the different biopsies analyzed was observed.
Two of the eleven analyzed genes involved in apoptosis 
presented statistically significant differences (p <0.05): cysteine 
protease 3 (CASP3, which is processed by caspases 8, 9 and 10 and 
participates in the execution of the signaling cascade of cellular 
apoptosis, activating caspases 6, 7 and 9) and tumor necrosis factor 
receptor family member 1A gene (TNFRS1A) (which induces cell 
death signaling through caspase 8). In both cases, these genes are 
slightly over expressed in affected vitiligo skin, indicating the in-
duction of an extrinsic apoptoticpathway. Previously, Kumar R et al. 
(2011) reported an increase in CASP3 levels in melanocyte cultures 
obtained from samples of unstable vitiligo using cell cultures and 
immune fluorescence techniques.46
For the TNFRS1A gene, no alterations in the expression lev-
els in the different skin types of vitiligo patients have been reported.
However, two of the four selected genes related to cell 
survival showed some pattern of differential expression between 
the skin types (p <0.05). Among these genes, the CDC5L gene, 
involved in cell cycle control, and the MITF gene, which controls 
the expression of genes related to melanin synthesis and melanocyte 
survival, showed higher expression patterns for pigmented tissues 
(not affected and repigmented) compared to affected vitiligo skin 
and skin that did not repigment after treatment. Kingo et al. (2008) 
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published a similar observation for the MITF gene using real-time 
PCR expression analysis. In their study, MITF showed higher 
expression patterns in skin from healthy controls and the unaffected 
skin of vitiligo patients compared to skin affected with vitiligo 
lesions.9A decrease in the expression pattern of the CDC5L gene 
was observed in skin that repigmented after treatment compared 
to affected vitiligo and unaffected skin before treatment. However, 
the participation of this gene in vitiligo has not yet been described.
For the genes involved in responses to oxidative stress, the 
GPD1 gene, involved in the oxidation-reduction metabolism of the 
cell (redox),38 was over expressed in tissue that repigmented after 
treatment. The TXN gene, involved in the inhibition of oxidative 
stress and activation of caspase 3, is over expressed in vitiligo and 
non-repigmented tissues, suggesting potential activation mech-
anisms in response to apoptosis and oxidative stress generated 
through mechanisms of cell death.
To date, only changes in the levels of TXN protein in the 
skin of vitiligo patients,39 and their relationship to the control of re-
active oxygen species production and UV damage have been report-
ed.47 The involvement of the GPD1 gene in the control of oxidative 
stress in vitiligo has not yet been explored.
Finally, the involvement of the WNT pathway in melano-
cyte differentiation and the development of vitiligo has recently 
been described.30 However, in our study, only statistically significant 
differences in the expression patterns observed for the CSNK1G3 
gene were seen. The product of this gene is a serine/threonine 
kinase that phosphorylates a number of proteins involved in the 
WNT pathway, participating in important cellular processes, such 
as DNA repair, cell division, nucleus-cytoplasmic shuttling of tran-
scription factors, and transport through the membrane. As shown in 
table 1, an increase in the levels of vitiligo-affected skin expression 
may reflect, among other processes, the activation of DNA repair 
mechanisms in damaged melanocyte/keratinocyte cells. However, 
a decrease in the expression of this gene was observed in affected 
skin that did not repigment after treatment, which may account for 
a decrease in the cellular mechanisms underlying melanocyte dif-
ferentiation and DNA repair in the damaged cells of skin affected 
with vitiligo.
CONCLUSION
The nb-UVB phototherapy produced significant changes in 
the expression patterns of the genes analyzed, primarily reflecting 
repigmentation and cellular apoptosis control.
Expression analysis revealed significant differences in the 
expression patterns of the DCT, MLANA and TYRP1 genes in pig-
mented skin (unaffected and affected then repigmented after treat-
ment) compared to affected skin (vitiligo and non-pigmented skin 
after treatment). The statistical analysis of the expression patterns 
obtained using TruSeq Targeted RNA Expression technology from 
skin samples obtained before and after treatment showed changes 
in the expression profiles in selected genes in response to nb-UVB 
phototherapy, and some of these changes were comparable with 
those previously reported by other research groups, particularly in 
genes related to skin pigmentation.
In addition, the identification of novel targets genes, in-
cluding TNFRS1A, GPD1 and CSNK1G3, implicated in apoptosis, 
oxidative stress control and signal transduction, suggests that these 
genes play a central role in many aspects of vitiligo development. 
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